TABLE 4.
In vitro susceptibilities of Candida albicans reference strain and clinical isolates to oligopeptide and amino acid antifungals and fluconazole
| Compound | MIC (μg/ml) ofa:
|
||||
|---|---|---|---|---|---|
| ATCC 10261 | Gu4 | Gu5 (CDR1 and/or CDR2) | B3 | B4 (MDR1) | |
| OLys-Leu-Gly (2) | 128 | 256 | 16 | 64 | 32 |
| Leu-FPhe (5) | 64 | 128 | 8 | 64 | 64 |
| Met-Met-FPhe (6) | 128 | 128 | 32 | 128 | 128 |
| Nva-FMDP (7) | 2 | 2 | 0.125 | 4 | 4 |
| Lys-Nva-FMDP (8) | 8 | 4 | 1 | 8 | 8 |
| Nikkomycin (9) | 32 | 16 | 4 | 8 | 8 |
| Histatin 5 | 32 | 32 | 32 | 32 | 32 |
| Asp-γ-hydroxamate (10) | 256 | 256 | 128 | 256 | 256 |
| OLys (11) | 16 | 16 | 4 | 16 | 32 |
| FPhe (12) | 256 | 128 | 128 | 128 | 128 |
| cis-pentacin (13) | 1 | 1 | 4 | 2 | 8 |
| DON (14) | 4 | 4 | 1 | 4 | 4 |
| Azaserine (15) | 16 | 16 | 16 | 32 | 32 |
| Fluconazole | 4 | 8 | 256 | 4 | 64 |
a
MICs were determined by using RPMI-1640 buffered medium, as described in Materials and Methods. No growth inhibition was observed for oligopeptides 1, 3, and 4 at a concentration of ≤1,024 μg/ml.